EU approves Ojemda as first targeted therapy for pediatric low-grade glioma

Pediatric low-grade glioma patients face profound lifelong neurological impairments including vision loss, speech difficulties, and motor dysfunction; this therapy offers relief from invasive surgical and chemotherapy burdens affecting children's education and independence.

On a spring morning in Paris, European regulators extended a rare mercy to hundreds of children each year whose slow-moving but devastating brain tumors had outlasted every prior treatment. The European Commission's approval of tovorafenib — the first targeted therapy for pediatric low-grade glioma across the EU — arrives not merely as a clinical milestone, but as a quiet rebuke to a pharmaceutical landscape where children's diseases have long been left to wait. In a field where only one in ten new drug approvals addresses pediatric illness, this decision asks what it means to measure progress

EU approves Ojemda as first targeted therapy for pediatric low-grade glioma

Cobertura Relacionada

Receba o Register no seu e-mail